Technology
We have developed novel Dead-Cert® technology for the detection and depletion of non-viable cells in vitro. This technology permits a step change in the efficiency with which we generate, culture, store and deliver cells for all purposes ranging from functional in vitro assays to therapeutic applications. Our products are designed for R&D uses and for GMP-compliant production and delivery of therapeutic cells and proteins. Combining our antibody development and engineering expertise – which we also offer as a flexible service to customers – we are developing novel anti-cancer biopharmaceuticals targeting our immune responses to cell death in tumours.
Applications
Our Dead-Cert®technology can be applied to all animal cells in vitro for R&D purposes and for the improved development andsupply of diagnostics and therapeutic cells and proteins. Our antibody engineering capabilities provide solutions ranging from in vitro assay reagent development to therapeutic antibody construction.
.jpg)
Benefits
By emulating the way our tissues are protected from the inhibitory effects of dead cells, our Dead-Cert® technology improves quality and supply of cell populations for any application, including research, bioprocessing and therapy. Through our proven and flexible antibody engineering resources, we are able to offer services tailored to customers' specific needs.
Partnership Opportunities
We are seeking investment, collaborative and business development partnerships to expand our business globally, particularly in the regenerative medicine and antibody therapeutics sectors.